ClinicalTrials.gg
CompletedNCT05843708Updated Feb 14, 2025

A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects

A Phase 1 interventional study of Vorasidenib 40 mg Oral Tablet and Ciprofloxacin 500 mg Oral Tablet in Healthy Subjects, sponsored by Servier Bio-Innovation LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-14.

Sponsored by Servier Bio-Innovation LLC · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The objectives of this study are:

  • To evaluate the effect of a low-fat meal on the pharmacokinetics (PK) of vorasidenib following a single oral dose of 40 mg vorasidenib in healthy adult subjects (substudy A)
  • To evaluate the effect of multiple-dose ciprofloxacin (strong cytochrome P450 [CYP]1A2 inhibitor) on the single-dose PK of vorasidenib in healthy adult subjects (substudy B)
02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Servier Bio-Innovation LLC is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is male or non-pregnant, non-lactating female 18 to 55 years of age, inclusive.
  2. The subject has a 18 to 32 kg/m2, inclusive, at screening.
  3. The subject has normal hepatic function ( [AST], alanine transaminase [ALT], total and direct , [INR] all ≤ [ULN]).
  4. The subject has normal renal function as evidenced by >90 mL/min based on the Cockcroft-Gault estimation: (140 - Age) × (Weight in kg) × (0.85 if female) / (72 × serum creatinine).
  5. The subject is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead results, and physical examination findings at screening and check-in.
  6. Female subjects of must use 2 effective methods of (eg, diaphragm with spermicide, intrauterine device, condom with foam or vaginal spermicide) or abstinence [true abstinence when this is in line with the preferred and usual lifestyle of the subject]) during the study and for 90 days after the last dose of vorasidenib or be surgically sterile (eg, hysteroscopic sterilization, bilateral tubal ligation or bilateral salpingectomy, hysterectomy, or bilateral oophorectomy), or (defined as amenorrhea 12 consecutive months and documented plasma follicle-stimulating hormone level >40 IU/mL). Female subjects must have a negative pregnancy test at screening and before the first dose of study drug.
  7. Male subjects with female partners of childbearing potential must be sterile or be willing to use 2 effective methods of birth control from screening until at least 90 days after the last dose of study drug, or practice abstinence during the study and for 90 days after the last dose of study drug. Abstinence is acceptable only as true abstinence when this is in line with the preferred and usual lifestyle of the subject. Male subjects should also agree to not donate sperm for the duration of the study and until at least 90 days after the last dose of study drug.
  8. The subject is a continuous nonsmoker who has not used nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) for at least 3 months prior to the first dose of study drug, based on cotinine test result.
  9. The subject agrees to comply with all protocol requirements for the duration of the study.
  10. The subject is able to provide written prior to any procedure required by the study.

Exclusion criteria

Exclusion Criteria:

  1. The subject has a history or clinical manifestations of a significant neurological, renal, cardiovascular, gastrointestinal, hepatic, pulmonary, hematologic, immunologic, or psychiatric disease that would preclude study participation, as judged by the investigator.
  2. The subject has a history (within 5 years prior to screening) or presence of , except for adequately treated basal cell and squamous cell carcinoma of the skin.
  3. The subject has a history of severe and/or uncontrolled ventricular arrhythmias, or other factors that increase the risk of or arrhythmic events (eg, heart failure, hypomagnesemia, hypokalemia, family history of long QT interval syndrome) or the subject was taking medications that are known to prolong the QT interval unless they can be safely discontinued ≥30 days or 5 half-lives (whichever is longer) before dosing.
  4. The subject has any surgical or medical condition(s) possibly affecting drug absorption, distribution, metabolism, and excretion (eg, cholecystectomy, bariatric procedure). Subjects with appendectomy may be included.
  5. The subject is a woman of who is pregnant, lactating, or planning to become pregnant within 90 days after the last dose of study drug, or the subject is on oral pills (moderate CYP1A2 inhibitors) within 14 days or 5 half-lives (whichever is longer) prior to the first dose administration and/or during the study.
  6. The subject has a positive test result for surface antigen or antibodies to virus (HCV) (if antibody test result is positive, it will be followed up with an HCV RNA test to confirm; those with undetectable HCV RNA will not be excluded).
  7. The subject has a positive test result for (HIV) type 1 or 2 antibodies at screening.
  8. The subject has a positive test result for the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at check-in (Day -1). The subject has received the coronavirus disease 2019 (COVID-19) vaccine within 7 days prior to screening or plans to receive a COVID-19 vaccine within 7 days after receiving the study drug.
  9. The subject has used strong CYP1A2 inhibitors and/or inducers within 14 days or 5 half-lives, whichever is longer, prior to the first dose administration and during the study (with the exception of study-specified ciprofloxacin during the study for subjects on Substudy B).
  10. The subject has received any vaccine or used any prescription (including hormonal birth control) or over-the-counter medications (except acetaminophen/paracetamol [up to 2 g per day]), including herbal or nutritional supplements, within 30 days or 5 drug half-lives whichever is longer (for all vaccines/medications other than hormonal birth control), or within 14 days or 5 drug half-lives, whichever is longer (for hormonal birth control medications), before the first dose of study drug and throughout the study. Hormone replacement therapy will not be allowed.
  11. The subject has consumed grapefruit or grapefruit juice, Seville orange or Seville orange-containing products (eg, marmalade), or caffeine- or xanthine-containing products within 48 hours before the first dose of study drug.
  12. The subject has a history of symptomatic hypoglycemia or hypoglycemia requiring intervention.
  13. The subject has a history of alcoholism or drug abuse within 3 months before screening, or excessive alcohol consumption (regular alcohol intake >21 units per week for male subjects and >14 units of alcohol per week for female subjects) (1 unit is equal to approximately ½ pint [200 mL] of beer, 1 small glass [100 mL] of wine, or 1 measure [25 mL] of spirits).
  14. The subject has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at screening or before the first dose of study drug.
  15. The subject is unable or unwilling to abstain from recreational drugs, alcohol, caffeine, xanthine-containing beverages or food (eg, coffee, tea, chocolate, and caffeinated sodas, colas), grapefruit, grapefruit juice, Seville oranges, or products containing any of these, from 48 hours prior to study drug dosing until EOS.
  16. The subject has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or designee, within the 30 days prior to the first dosing and throughout the study.
  17. The subject is involved in strenuous activity (>30 min per day) or contact sports within 48 to 72 hours before dosing and during the study.
  18. The subject has excessive exposure to natural or artificial sunlight (tanning beds or UV A/B treatment) within 48 to 72 hours before dosing and during the study.
  19. The subject has donated blood or blood products >450 mL within 30 days before the first dose of study drug.
  20. The subject has a history of any , allergy, or other to the components of the vorasidenib, ciprofloxacin, or activated charcoal formulations used in this study or any significant food allergy.
  21. The subject was exposed to an drug (new chemical entity) within 30 days preceding the first dose administration, or 5 half-lives of that investigational drug, if known (whichever is longer).
  22. The subject is part of the clinical staff personnel or a family member of the clinical site staff.
  23. In the opinion of the investigator, the subject is not suitable for entry into the study.

    Additional Exclusion Criteria for Substudy B:

  24. The subject has hypersensitivity to any fluoroquinolone.
  25. The subject is at increased risk of Clostridium difficile (eg, prior history of C. difficile infection, recent use of systemic antibiotics [oral, intramuscular, or intravenous] in the last 6 months, recent abdominal surgery within 3 months prior to check-in, history of inflammatory bowel disease, or as judged by the investigator).
  26. The subject has had any medical condition that has required frequent or repeat course of antibiotics within the last 6 months. (eg recurrent urinary tract infection [UTI], strep pharyngitis, otitis media, or as judged by the investigator).
  27. The subject has any history of tendon rupture or known vascular abnormality.
  28. The subject is unable or unwilling to abstain from dairy products or mineral fortified drinks (eg, milk, yogurt, calcium-fortified orange juice) from 48 hours prior to study drug dosing until discharge.
  29. The subject has useD of glyburide, cyclosporine, didanosine, methotrexate, or probenecid within 30 days prior to Day 1 or within 5 half-lives of Day 1, whichever is longer.
  30. The subject is at high risk for QT prolongation, including:

    1. Baseline QTcF ≥ 450 msec
    2. Risk factors for Torsade de Pointes, including hypocalcemia, hypokalemia, hypomagnesemia, sudden death of unknown cause in a close family member (ie, biological mother, father, or siblings), a near drowning episode, a family history of long QT syndrome.
  31. The subject has any history of photosensitivity, including, but not limited to a history of phototoxic and/or photoallergic reactions to medications as determined by the investigator
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Fasting condition / Low-fat meal

    A single oral dose of 1×40 mg vorasidenib tablet administered under fasted conditions or following a low-fat meal.

    Drug: Vorasidenib 40 mg Oral Tablet

  • Experimental
    Low-fat meal / Fasted condition

    A single oral dose of 1×40 mg vorasidenib tablet administered following a low-fat meal or under fasted conditions.

    Drug: Vorasidenib 40 mg Oral Tablet

  • Experimental
    Vorasidenib

    Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1.

    Drug: Vorasidenib 10 mg Oral Tablet

  • Experimental
    Vorasidenib and ciprofloxacin

    Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 and twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14.

    Drug: Ciprofloxacin 500 mg Oral Tablet · Drug: Vorasidenib 10 mg Oral Tablet

Interventions

  • Single oral dose of 1×40 mg vorasidenib tablet administered : * under fasted conditions (all subjects will fast overnight for at least 10 hours prior to dosing and for at least 4 hours after dosing. * or following a low fat meal (approximatively 400 to 500 calories) (Substudy A)

  • Twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14 (Substudy B)

  • Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 (Substudy B)

06

What researchers measure

Primary outcomes

  1. Cmax of Vorasidenib (substudy A)

    Maximum observed plasma concentration of vorasidenib in substudy A

    Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose

  2. Tmax of Vorasidenib (substudy A)

    Time to maximum observed plasma concentration of vorasidenib in substudy A

    Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose

  3. AUC0-t of Vorasidenib (substudy A)

    Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t) of vorasidenib in substudy A

    Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose

  4. AUC0-inf of Vorasidenib (substudy A)

    AUC from time 0 extrapolated to infinity (AUC0-inf) of vorasidenib in substudy A

    Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose

  5. Cmax of Vorasidenib (substudy B)

    Maximum observed plasma concentration of vorasidenib in substudy B

    Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.

  6. Tmax of Vorasidenib (substudy B)

    Time to maximum observed plasma concentration of vorasidenib in substudy B

    Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.

  7. AUC0-t of Vorasidenib (substudy B)

    Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t) of vorasidenib in substudy B

    Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.

  8. AUC0-inf of Vorasidenib (substudy B)

    AUC from time 0 extrapolated to infinity (AUC0-inf) of vorasidenib in substudy B

    Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.

Secondary outcomes

  1. T1/2 of Vorasidenib (Substudy A)

    Half-life f vorasidenib in substudy A

    Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose

  2. CL/F of Vorasidenib (Substudy A)

    Apparent oral clearance of vorasidenib in substudy A

    Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose

  3. Vz/F of Vorasidenib (Substudy A)

    Apparent volume of distribution of vorasidenib in substudy A

    Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose

  4. Cmax of AGI-69460 (Substudy A)

    Maximum observed plasma concentration of AGI-69460 in substudy A

    Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose

  5. Tmax of AGI-69460 (substudy A)

    Time to maximum observed plasma concentration of AGI-69460 (substudy A)

    Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose

  6. AUC0-t of AGI-69460 (substudy A)

    Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t) of AGI-69460 (substudy A)

    Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose

  7. AUC0-inf of AGI-69460 (substudy A)

    AUC from time 0 extrapolated to infinity (AUC0-inf) of AGI-69460 (substudy A)

    Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose

  8. T1/2 of vorasidenib (substudy B)

    Half-life of vorasidenib in substudy B

    Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.

  9. CL/F of vorasidenib (substudy B)

    Apparent oral clearance of vorasidenib in substudy B

    Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.

  10. Vz/f

    Apparent volume of distribution of vorasidenib in substudy B

    Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.

  11. Cmax of AGI-69460 (substudy B)

    Maximum observed plasma concentration of AGI-69460 in substudy B

    Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.

  12. Tmax of AGI-69460 (substudy B)

    Time to maximum observed plasma concentration of AGI-69460 (substudy B)

    Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.

  13. AUC0-t of AGI-69460 (substudy B)

    Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration of AGI-69460 (substudy B)

    Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.

  14. AUC0-inf of AGI-69460 (substudy B)

    AUC from time 0 extrapolated to infinity (AUC0-inf) of AGI-69460 (substudy B)

    Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.

  15. Cmax of ciprofloxacin (substudy B)

    Maximum observed plasma concentration of ciprofloxacin in substudy B

    Time frame: Before dosing on Day 18 and on multiple time points up to 12 h after dosing

  16. Tmax of ciprofloxacin (substudy B)

    Tmax of ciprofloxacine (substudy B)

    Time frame: Before dosing on Day 18 and on multiple time points up to 12 h after dosing

  17. AUC0-t of ciprofloxacin (substudy B)

    Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration of ciprofloxacin (substudy B)

    Time frame: Before dosing on Day 18 and on multiple time points up to 12 h after dosing

  18. AUC0-12 of ciprofloxacin (substudy B)

    Area under the plasma concentration versus time curve (AUC) from time 0 to 12h of ciprofloxacin (substudy B)

    Time frame: Before dosing on Day 18 and on multiple time points up to 12 h after dosing

07

Study locations

1 site
  • PPD Development
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After Marketing Authorisation in EEA or US if the study is used for the approval

Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed

Data sharing details ↗ · clinicaltrials.servier.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Jul 2023, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2023
First posted
May 6, 2023
StartActual
Apr 14, 2023
Primary completionActual
Jul 28, 2023
CompletionActual
Jul 28, 2023
Last update
Feb 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05843708
Lead sponsor
Servier Bio-Innovation LLC
Collaborators
Institut de Recherches Internationales Servier
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Apr 14, 2023
Primary completion
Jul 28, 2023
Completion
Jul 28, 2023
Last update
Feb 14, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vorasidenib · Ciprofloxacin

Start the discussion